Company / R&D Expense
Steris R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$107.6M
FY2024
5-year range
$86.7M / $107.6M
FY2020-FY2024
Trend
+3.8%
vs FY2023
Sector context
#51 of 105
Health Care
What the data says
At $108M, Steris's r&d expense ranks #51 of 105 in the Health Care sector. R&D Expense has increased for 7 consecutive years, from $59M in FY2016 to $108M in FY2024.
Based on SEC 10-K filings.
$108M in FY2024 with a 5-year CAGR of +10.4%.
Improved from $98M to $108M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.5%
- 5-Year CAGR
- +10.4%
- 10-Year CAGR
- -
Sector benchmark
#51 of 105 in Health CareTop 49% of 105This company $107.6M Sector average $284.2M
▼
-62.1% below sector average
Key checks
Key Insights
- Steris's r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +10.4%, indicating consistent growth.
- In FY2024, r&d expense increased 3.8% year-over-year.
- Ranks #51 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $107.6M | +3.8% |
| FY2023 | $103.7M | +5.3% |
| FY2022 | $98.5M | +13.6% |
| FY2021 | $86.7M | +30.7% |
| FY2020 | $66.3M | +1.2% |
| FY2019 | $65.5M | +4.0% |
| FY2018 | $63.0M | - |
| FY2017 | - | - |
| FY2016 | $59.4M | - |
As of FY2024 · SEC 10-K · Updated Mar 13, 2026